APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Xerostomia (Dry Mouth) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Xerostomia (Dry Mouth) Therapeutics Market Outlook and Growth Opportunities 2026

Report ID 17404807042 January 2026190 pages

Choose your research edition.

Industry ResearchXerostomia (Dry Mouth) Therapeutics Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Xerostomia (Dry Mouth) Therapeutics Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Xerostomia (Dry Mouth) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Xerostomia (Dry Mouth) Therapeutics Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Xerostomia (Dry Mouth) Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Xerostomia (Dry Mouth) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Xerostomia (Dry Mouth) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Xerostomia (Dry Mouth) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Xerostomia (Dry Mouth) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Xerostomia (Dry Mouth) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Xerostomia (Dry Mouth) Therapeutics market include Acacia Pharma, Church & Dwight, Inc., Colgate-Palmolive Company, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc., OraCoat, Parnell Pharmaceuticals, Inc., Pendopharm and GlaxoSmithKline plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Xerostomia (Dry Mouth) Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Xerostomia (Dry Mouth) Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Xerostomia (Dry Mouth) Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Xerostomia (Dry Mouth) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Xerostomia (Dry Mouth) Therapeutics Segment by Company

Acacia Pharma

Church & Dwight, Inc.

Colgate-Palmolive Company

Hikma Pharmaceuticals PLC

Lupin Pharmaceuticals, Inc.

OraCoat

Parnell Pharmaceuticals, Inc.

Pendopharm

GlaxoSmithKline plc

Pfizer, Inc.

Sun Pharmaceuticals Industries Ltd.

Xerostomia (Dry Mouth) Therapeutics Segment by Type

Salivary Stimulants

Salivary Substitutes

Dentifrices

Xerostomia (Dry Mouth) Therapeutics Segment by Application

OTC

Prescription

Xerostomia (Dry Mouth) Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Xerostomia (Dry Mouth) Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Xerostomia (Dry Mouth) Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Xerostomia (Dry Mouth) Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Xerostomia (Dry Mouth) Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Xerostomia (Dry Mouth) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Xerostomia (Dry Mouth) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Xerostomia (Dry Mouth) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Xerostomia (Dry Mouth) Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Xerostomia (Dry Mouth) Therapeutics industry.

Chapter 3: Detailed analysis of Xerostomia (Dry Mouth) Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Xerostomia (Dry Mouth) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Xerostomia (Dry Mouth) Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Xerostomia (Dry Mouth) Therapeutics Industry Trends Table 2. Xerostomia (Dry Mouth) Therapeutics Industry Drivers Table 3. Xerostomia (Dry Mouth) Therapeutics Industry Opportunities and Challenges Table 4. Xerostomia (Dry Mouth) Therapeutics Industry Restraints Table 5. Global Xerostomia (Dry Mouth) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Xerostomia (Dry Mouth) Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Company (W Tons) & (2021-2026) Table 8. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global Xerostomia (Dry Mouth) Therapeutics Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Xerostomia (Dry Mouth) Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Xerostomia (Dry Mouth) Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global Xerostomia (Dry Mouth) Therapeutics Company, Product Type & Application Table 13. Global Xerostomia (Dry Mouth) Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Xerostomia (Dry Mouth) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Salivary Stimulants Table 18. Significant Companies of Salivary Substitutes Table 19. Significant Companies of Dentifrices Table 20. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (W Tons) Table 21. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Type (2021-2026) & (W Tons) Table 22. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Type (2027-2032) & (W Tons) Table 23. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume Share by Type (2021-2026) Table 24. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume Share by Type (2027-2032) Table 25. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type (2021-2026) Table 29. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type (2027-2032) Table 30. Significant Companies of OTC Table 31. Significant Companies of Prescription Table 32. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (W Tons) Table 33. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Application (2021-2026) & (W Tons) Table 34. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Application (2027-2032) & (W Tons) Table 35. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume Share by Application (2021-2026) Table 36. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume Share by Application (2027-2032) Table 37. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application (2021-2026) Table 41. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application (2027-2032) Table 42. Global Xerostomia (Dry Mouth) Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Table 43. Global Xerostomia (Dry Mouth) Therapeutics Sales by Region (2021-2026) & (W Tons) Table 44. Global Xerostomia (Dry Mouth) Therapeutics Sales Market Share by Region (2021-2026) Table 45. Global Xerostomia (Dry Mouth) Therapeutics Sales by Region (2027-2032) & (W Tons) Table 46. Global Xerostomia (Dry Mouth) Therapeutics Sales Market Share by Region (2027-2032) Table 47. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Region (2021-2026) Table 50. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Region (2027-2032) Table 52. Global Xerostomia (Dry Mouth) Therapeutics Market Average Price (US$/Ton) by Region (2021-2026) Table 53. Global Xerostomia (Dry Mouth) Therapeutics Market Average Price (US$/Ton) by Region (2027-2032) Table 54. Global Xerostomia (Dry Mouth) Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Table 55. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2026) & (W Tons) Table 57. Global Xerostomia (Dry Mouth) Therapeutics Sales Market Share by Country (2021-2026) Table 58. Global Xerostomia (Dry Mouth) Therapeutics Sales by Country (2027-2032) & (W Tons) Table 59. Global Xerostomia (Dry Mouth) Therapeutics Sales Market Share by Country (2027-2032) Table 60. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Market Share by Country (2021-2026) Table 62. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Market Share by Country (2027-2032) Table 64. Acacia Pharma Company Information Table 65. Acacia Pharma Business Overview Table 66. Acacia Pharma Xerostomia (Dry Mouth) Therapeutics Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 67. Acacia Pharma Xerostomia (Dry Mouth) Therapeutics Product Portfolio Table 68. Acacia Pharma Recent Development Table 69. Church & Dwight, Inc. Company Information Table 70. Church & Dwight, Inc. Business Overview Table 71. Church & Dwight, Inc. Xerostomia (Dry Mouth) Therapeutics Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 72. Church & Dwight, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio Table 73. Church & Dwight, Inc. Recent Development Table 74. Colgate-Palmolive Company Company Information Table 75. Colgate-Palmolive Company Business Overview Table 76. Colgate-Palmolive Company Xerostomia (Dry Mouth) Therapeutics Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 77. Colgate-Palmolive Company Xerostomia (Dry Mouth) Therapeutics Product Portfolio Table 78. Colgate-Palmolive Company Recent Development Table 79. Hikma Pharmaceuticals PLC Company Information Table 80. Hikma Pharmaceuticals PLC Business Overview Table 81. Hikma Pharmaceuticals PLC Xerostomia (Dry Mouth) Therapeutics Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 82. Hikma Pharmaceuticals PLC Xerostomia (Dry Mouth) Therapeutics Product Portfolio Table 83. Hikma Pharmaceuticals PLC Recent Development Table 84. Lupin Pharmaceuticals, Inc. Company Information Table 85. Lupin Pharmaceuticals, Inc. Business Overview Table 86. Lupin Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 87. Lupin Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio Table 88. Lupin Pharmaceuticals, Inc. Recent Development Table 89. OraCoat Company Information Table 90. OraCoat Business Overview Table 91. OraCoat Xerostomia (Dry Mouth) Therapeutics Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 92. OraCoat Xerostomia (Dry Mouth) Therapeutics Product Portfolio Table 93. OraCoat Recent Development Table 94. Parnell Pharmaceuticals, Inc. Company Information Table 95. Parnell Pharmaceuticals, Inc. Business Overview Table 96. Parnell Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 97. Parnell Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio Table 98. Parnell Pharmaceuticals, Inc. Recent Development Table 99. Pendopharm Company Information Table 100. Pendopharm Business Overview Table 101. Pendopharm Xerostomia (Dry Mouth) Therapeutics Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 102. Pendopharm Xerostomia (Dry Mouth) Therapeutics Product Portfolio Table 103. Pendopharm Recent Development Table 104. GlaxoSmithKline plc Company Information Table 105. GlaxoSmithKline plc Business Overview Table 106. GlaxoSmithKline plc Xerostomia (Dry Mouth) Therapeutics Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 107. GlaxoSmithKline plc Xerostomia (Dry Mouth) Therapeutics Product Portfolio Table 108. GlaxoSmithKline plc Recent Development Table 109. Pfizer, Inc. Company Information Table 110. Pfizer, Inc. Business Overview Table 111. Pfizer, Inc. Xerostomia (Dry Mouth) Therapeutics Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 112. Pfizer, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio Table 113. Pfizer, Inc. Recent Development Table 114. Sun Pharmaceuticals Industries Ltd. Company Information Table 115. Sun Pharmaceuticals Industries Ltd. Business Overview Table 116. Sun Pharmaceuticals Industries Ltd. Xerostomia (Dry Mouth) Therapeutics Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 117. Sun Pharmaceuticals Industries Ltd. Xerostomia (Dry Mouth) Therapeutics Product Portfolio Table 118. Sun Pharmaceuticals Industries Ltd. Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Xerostomia (Dry Mouth) Therapeutics Distributors List Table 122. Xerostomia (Dry Mouth) Therapeutics Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Xerostomia (Dry Mouth) Therapeutics Product Image Figure 2. Global Xerostomia (Dry Mouth) Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Xerostomia (Dry Mouth) Therapeutics Sales (2021-2032) & (W Tons) Figure 5. Global Xerostomia (Dry Mouth) Therapeutics Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Xerostomia (Dry Mouth) Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Salivary Stimulants Image Figure 10. Salivary Substitutes Image Figure 11. Dentifrices Image Figure 12. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (W Tons) Figure 13. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume Share by Type (2021-2032) Figure 15. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type (2021-2032) Figure 18. OTC Image Figure 19. Prescription Image Figure 20. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (W Tons) Figure 21. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Xerostomia (Dry Mouth) Therapeutics Sales Volume Share by Application (2021-2032) Figure 23. Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application (2021-2032) Figure 26. Global Xerostomia (Dry Mouth) Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Figure 27. Global Xerostomia (Dry Mouth) Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. North America Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 37. South America Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Xerostomia (Dry Mouth) Therapeutics Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Xerostomia (Dry Mouth) Therapeutics Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Salivary Stimulants
  • Salivary Substitutes
  • Dentifrices
Applications
  • OTC
  • Prescription
Companies covered
  • Acacia Pharma
  • Church & Dwight, Inc.
  • Colgate-Palmolive Company
  • Hikma Pharmaceuticals PLC
  • Lupin Pharmaceuticals, Inc.
  • OraCoat
  • Parnell Pharmaceuticals, Inc.
  • Pendopharm
  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Sun Pharmaceuticals Industries Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global Xerostomia (Dry Mouth) Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Xerostomia (Dry Mouth) Therapeutics Market Dynamics
  1. 2.1 Xerostomia (Dry Mouth) Therapeutics Industry Trends
  2. 2.2 Xerostomia (Dry Mouth) Therapeutics Industry Drivers
  3. 2.3 Xerostomia (Dry Mouth) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Xerostomia (Dry Mouth) Therapeutics Industry Restraints
3 Xerostomia (Dry Mouth) Therapeutics Market by Company
  1. 3.1 Global Xerostomia (Dry Mouth) Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Xerostomia (Dry Mouth) Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global Xerostomia (Dry Mouth) Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global Xerostomia (Dry Mouth) Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global Xerostomia (Dry Mouth) Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global Xerostomia (Dry Mouth) Therapeutics Company Product Type and Application
  8. 3.8 Global Xerostomia (Dry Mouth) Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Xerostomia (Dry Mouth) Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Xerostomia (Dry Mouth) Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Xerostomia (Dry Mouth) Therapeutics Market by Type
  1. 4.1 Xerostomia (Dry Mouth) Therapeutics Type Introduction
  2. 4.1.1 Salivary Stimulants
  3. 4.1.2 Salivary Substitutes
  4. 4.1.3 Dentifrices
  5. 4.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Type
  6. 4.2.1 Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Xerostomia (Dry Mouth) Therapeutics Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Type
  10. 4.3.1 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Type (2021-2032)
  12. 4.3.3 Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type (2021-2032)
5 Xerostomia (Dry Mouth) Therapeutics Market by Application
  1. 5.1 Xerostomia (Dry Mouth) Therapeutics Application Introduction
  2. 5.1.1 OTC
  3. 5.1.2 Prescription
  4. 5.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Application
  5. 5.2.1 Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Xerostomia (Dry Mouth) Therapeutics Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Application
  9. 5.3.1 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Application (2021-2032)
  11. 5.3.3 Global Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application (2021-2032)
6 Xerostomia (Dry Mouth) Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Xerostomia (Dry Mouth) Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global Xerostomia (Dry Mouth) Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global Xerostomia (Dry Mouth) Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Xerostomia (Dry Mouth) Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Xerostomia (Dry Mouth) Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global Xerostomia (Dry Mouth) Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global Xerostomia (Dry Mouth) Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Xerostomia (Dry Mouth) Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Xerostomia (Dry Mouth) Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Xerostomia (Dry Mouth) Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Acacia Pharma
  2. 8.1.1 Acacia Pharma Company Information
  3. 8.1.2 Acacia Pharma Business Overview
  4. 8.1.3 Acacia Pharma Xerostomia (Dry Mouth) Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Acacia Pharma Xerostomia (Dry Mouth) Therapeutics Product Portfolio
  6. 8.1.5 Acacia Pharma Recent Developments
  7. 8.2 Church & Dwight, Inc.
  8. 8.2.1 Church & Dwight, Inc. Company Information
  9. 8.2.2 Church & Dwight, Inc. Business Overview
  10. 8.2.3 Church & Dwight, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Church & Dwight, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
  12. 8.2.5 Church & Dwight, Inc. Recent Developments
  13. 8.3 Colgate-Palmolive Company
  14. 8.3.1 Colgate-Palmolive Company Company Information
  15. 8.3.2 Colgate-Palmolive Company Business Overview
  16. 8.3.3 Colgate-Palmolive Company Xerostomia (Dry Mouth) Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Colgate-Palmolive Company Xerostomia (Dry Mouth) Therapeutics Product Portfolio
  18. 8.3.5 Colgate-Palmolive Company Recent Developments
  19. 8.4 Hikma Pharmaceuticals PLC
  20. 8.4.1 Hikma Pharmaceuticals PLC Company Information
  21. 8.4.2 Hikma Pharmaceuticals PLC Business Overview
  22. 8.4.3 Hikma Pharmaceuticals PLC Xerostomia (Dry Mouth) Therapeutics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hikma Pharmaceuticals PLC Xerostomia (Dry Mouth) Therapeutics Product Portfolio
  24. 8.4.5 Hikma Pharmaceuticals PLC Recent Developments
  25. 8.5 Lupin Pharmaceuticals, Inc.
  26. 8.5.1 Lupin Pharmaceuticals, Inc. Company Information
  27. 8.5.2 Lupin Pharmaceuticals, Inc. Business Overview
  28. 8.5.3 Lupin Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lupin Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
  30. 8.5.5 Lupin Pharmaceuticals, Inc. Recent Developments
  31. 8.6 OraCoat
  32. 8.6.1 OraCoat Company Information
  33. 8.6.2 OraCoat Business Overview
  34. 8.6.3 OraCoat Xerostomia (Dry Mouth) Therapeutics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 OraCoat Xerostomia (Dry Mouth) Therapeutics Product Portfolio
  36. 8.6.5 OraCoat Recent Developments
  37. 8.7 Parnell Pharmaceuticals, Inc.
  38. 8.7.1 Parnell Pharmaceuticals, Inc. Company Information
  39. 8.7.2 Parnell Pharmaceuticals, Inc. Business Overview
  40. 8.7.3 Parnell Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Parnell Pharmaceuticals, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
  42. 8.7.5 Parnell Pharmaceuticals, Inc. Recent Developments
  43. 8.8 Pendopharm
  44. 8.8.1 Pendopharm Company Information
  45. 8.8.2 Pendopharm Business Overview
  46. 8.8.3 Pendopharm Xerostomia (Dry Mouth) Therapeutics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pendopharm Xerostomia (Dry Mouth) Therapeutics Product Portfolio
  48. 8.8.5 Pendopharm Recent Developments
  49. 8.9 GlaxoSmithKline plc
  50. 8.9.1 GlaxoSmithKline plc Company Information
  51. 8.9.2 GlaxoSmithKline plc Business Overview
  52. 8.9.3 GlaxoSmithKline plc Xerostomia (Dry Mouth) Therapeutics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline plc Xerostomia (Dry Mouth) Therapeutics Product Portfolio
  54. 8.9.5 GlaxoSmithKline plc Recent Developments
  55. 8.10 Pfizer, Inc.
  56. 8.10.1 Pfizer, Inc. Company Information
  57. 8.10.2 Pfizer, Inc. Business Overview
  58. 8.10.3 Pfizer, Inc. Xerostomia (Dry Mouth) Therapeutics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer, Inc. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
  60. 8.10.5 Pfizer, Inc. Recent Developments
  61. 8.11 Sun Pharmaceuticals Industries Ltd.
  62. 8.11.1 Sun Pharmaceuticals Industries Ltd. Company Information
  63. 8.11.2 Sun Pharmaceuticals Industries Ltd. Business Overview
  64. 8.11.3 Sun Pharmaceuticals Industries Ltd. Xerostomia (Dry Mouth) Therapeutics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Sun Pharmaceuticals Industries Ltd. Xerostomia (Dry Mouth) Therapeutics Product Portfolio
  66. 8.11.5 Sun Pharmaceuticals Industries Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Xerostomia (Dry Mouth) Therapeutics Value Chain Analysis
  2. 9.1.1 Xerostomia (Dry Mouth) Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Xerostomia (Dry Mouth) Therapeutics Sales Mode & Process
  6. 9.2 Xerostomia (Dry Mouth) Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Xerostomia (Dry Mouth) Therapeutics Distributors
  9. 9.2.3 Xerostomia (Dry Mouth) Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst